More Evidence Needed For Chiesi’s Ultra Orphan Lamzede, Says NICE
Chiesi still has work to do to convince NICE that its ultra rare disease treatment Lamzede is a cost-effective treatment.
Chiesi still has work to do to convince NICE that its ultra rare disease treatment Lamzede is a cost-effective treatment.